Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fazarabine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fazarabine is a synthetic pyrimidine nucleoside analogue and an antimetabolite. Structurally, it is an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. It acts as an RNA synthesis inhibitor and was developed primarily for anticancer indications. Fazarabine has been investigated in clinical trials for various neoplasms, including advanced solid tumors and non-small cell lung cancer[1][2][3][4][8][9]. Its mechanism of action involves inhibition of RNA synthesis by incorporation into nucleic acids during DNA replication or repair processes.
- Brand names
- Kymarabine
- Other names
- arabinofuranosyl-5-azacytosinearabinofuranosyl5-azacytosinearabinofuranosyl 5-azacytosine1-beta-D-arabinofuranosyl-5-azacytosine
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on fazarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fazarabine.